去甲斑蝥素为前体的结构改造及联合用药抗癌研究进展

中国药物警戒 ›› 2019, Vol. 16 ›› Issue (3): 179-184.

去甲斑蝥素为前体的结构改造及联合用药抗癌研究进展

李轶群, 孙震晓^*

北京中医药大学生命科学学院,北京100102

收稿日期:2019-01-04 修回日期:2020-06-28 出版日期:2019-03-20 发布日期:2019-04-17
通讯作者: 孙震晓,女,博士,教授·博导,中药分子细胞药理学与毒理学研究。E-mail:sunzxcn@hotmail.com
作者简介:李轶群,男,在读硕士,中药抗肿瘤活性成分筛选与分子机制研究。
基金资助:
国家自然科学基金（81473418）：肝细胞色素P450酶表达低下致何首乌特异质肝毒性机制研究

Study Progress of Norcantharidin Based Structural Modification and Drug Combination for Cancer

LI Yiqun, SUN Zhenxiao^*

School of Life Science, Beijing University of Chinese Medicine, Beijing 100102,China

Received:2019-01-04 Revised:2020-06-28 Online:2019-03-20 Published:2019-04-17

摘要/Abstract

摘要： 去甲斑蝥素（norcantharidin,NCTD）是我国自行研制的一种抗癌药物,临床上具有广谱抗癌活性,并可升高外周血白细胞水平,常单独或与其他药物联合用于治疗肝癌、食道癌、胃癌、肺癌等。近年来为提高NCTD的抗肿瘤活性、减轻其可能的不良反应,以NCTD为前体的结构改造及与其他药物的联合使用等取得一定研究成果。本文通过对以NCTD为前体的新型抗癌化合物合成及筛选、NCTD联合其他药物抗癌的基础与临床研究最新进展进行综述,为基于NCTD的抗癌药物研发及临床应用提供参考。

关键词: 去甲斑蝥素, 抗癌, 结构改造, 联合用药, 不良反应

Abstract: Norcantharidin (NCTD) is an anticancer drug developed in China. It has broad-spectrum anticancer activity and can increase the level of peripheral blood leukocytes. It is often used alone or in combination with other drugs to treat liver cancer, esophageal cancer, stomach cancer, lung cancer, etc. To improve the antitumor activity and reduce its possible adverse reaction, the structure modification and drug combination of NCTD have made some progress in recent years. This paper tried to summarize the latest progress in structure modification and anticancer screening of NCTD, basic research and clinical studies of NCTD combined with other anticancer drugs, providing reference data for NCTD based new drug development and clinical application.

Key words: norcantharidin, anticancer, structure modification, drug combination, adverse reaction

中图分类号:

R965

李轶群, 孙震晓. 去甲斑蝥素为前体的结构改造及联合用药抗癌研究进展[J]. 中国药物警戒, 2019, 16(3): 179-184.

LI Yiqun, SUN Zhenxiao. Study Progress of Norcantharidin Based Structural Modification and Drug Combination for Cancer[J]. Chinese Journal of Pharmacovigilance, 2019, 16(3): 179-184.

参考文献

[1] 国家药典委员会.中华人民共和国药典(一部)[M]. 北京:中国医药科技出版社,2015:331-332.
[2] Wang G S.Medical uses of mylabris in ancient China and recent studies[J]. J Ethnopharmacol, 1989, 26(2):147-162.
[3] 孙震晓,李家实.去甲斑蝥素抗肿瘤研究热点[J].西北药学杂志,1998,13(5):227-229.
[4] 洪兴福, 李宝赛, 孙震晓. 去甲斑蝥素对体外微管蛋白聚合的抑制作用[J]. 中国药理学与毒理学杂志, 2012, 26(5):630-634.
[5] Zhao J, Guan X W, Chen S W, et al.Synthesis and biological evaluation of norcantharidin derivatives as protein phosphatase-1 inhibitors[J]. Bioorg Med Chem Lett, 2015, 25(2):363-366.
[6] Hou T, Xiao Z, Li Y, et al.Norcantharidin inhibits renal interstitial fibrosis by downregulating PP2Ac expression[J]. Am J Transl Res, 2015, 7(11):2199-2211.
[7] Wu M H, Chiou H L, Lin C L, et al.Induction of endoplasmic reticulum stress and mitochondrial dysfunction dependent apoptosis signaling pathway in human renal cancer cells by norcantharidin[J]. Oncotarget, 2018, 9(4):4787-4797.
[8] Lv H, Li Y, Du H, et al.The synthetic compound norcantharidin induced apoptosis in mantle cell lymphoma in vivo and in vitro through the PI3K-Akt-NF-κB signaling pathway[J]. Evid Based Complement Alternat Med, 2013, 2013(2):461-487.
[9] 陈静,崔宝弟,孙震晓.去甲斑蝥素作用早期对人肝癌细胞活性氧及NF-E2相关因子2/抗氧化反应元件信号通路的激活[J].中国药理学与毒理学杂志,2017,31(1):94-100.
[10] Wu Y, Cao C M, Wang H Q, et al.Norcantharidin downregulates programmed cell death 4 expression in human gastric cancer cells[J]. Chin J Pharmacol Toxicol, 2013, 27(4):622-628.
[11] Liu X H, Blazsek I, Comisso M, et al.Effects of norcantharidin, a protein phosphatase type-2A inhibitor, on the growth of normal and malignant haemopoietic cells[J]. Eur J Cancer, 1995, 31(6):953-963.
[12] 郑丹, 沙启明, 王剑青,等. 去甲斑蝥素对环磷酰胺诱导的白细胞减少症模型大鼠骨髓造血功能的影响[J]. 中国实验血液学杂志, 2015, 23(3):826-831.
[13] Hart M E, Chamberlin A R, Walkom C, et al.Modified norcantharidins; synthesis, protein phosphatases 1 and 2A inhibition, and anticancer activity[J]. Bioorg Med Chem, 2004, 14(8):1969-1973.
[14] Robertson M J, Gordon C P, Gilbert J, et al.Norcantharimide analogues possessing terminal phosphate esters and their anti-cancer activity[J]. Bioorg Med Chem Lett, 2011, 19(18):5734-5741.
[15] Han H W, Qiu H Y, Hu C, et al.Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs[J]. Bioorg Med Chem Lett, 2016, 26(14):3237-3242.
[16] Tang Z B, Chen Y Z, Zhao J, et al.Conjugates of podophyllotoxin and norcantharidin as dual inhibitors of topoisomeraseⅡ and protein phosphatase 2A[J]. Eur J Med Chem, 2016, 10(123):568-576.
[17] Ho Y P, To K, Au-Yeung S, et al.Potential New Antitumor Agents from an Innovative Combination of Demethylcantharidin, a Modified Traditional Chinese Medicine, with a Platinum Moiety[J]. J Med Chem, 2001, 44(13):2065-2068.
[18] Zhao C, Li C, Wang X, et al.The regio-selective synthesis of 10-hydroxy camptothecin norcantharidin conjugates and their biological activity evaluationin vitro[J]. R Soc Open Sci, 2018, 5(6):172317
[19] Wang X H, Yang F H, Zhao C K, et al.Sealed tube promoted coupling of camptothecin and norcantharidin acid ester and their preliminary biological activity evaluation in vitro[J]. Med Che Res, 2018, 27(2):406-411.
[20] 李亚男,迟金华,刘万顺,等.去甲斑蝥素-壳聚糖缓释制剂长期毒性研究[J].中国海洋药物,2017,36(5):33-41
[21] 范潇婷,于睿鹏,董瑞娟,等.斑蝥素及去甲斑蝥素对小鼠毒性靶器官的影响[J].中国实验方剂学杂志,2017,23(15):118-123.
[22] Wang X, Gu Z, Li G, et al.Norcantharidin enhances ABT-263-mediated anticancer activity in neuroblastoma cells by upregulation of Noxa[J]. Oncol Rep, 2014, 32(2):716-722.
[23] 李子木,孙震晓.伊立替康联合去甲斑蝥素对人胃癌细胞作用的考察及协同作用机制研究[J].生物化学与生物物理进展,2015,42(2):169-182
[24] 曹秋菊, 田志华, 孙晟,等. 人胃癌BGC-823细胞中去甲斑蝥素抑癌作用机理的蛋白质组学研究[J]. 生物化学与生物物理进展, 2009, 36(9):1114-1121.
[25] Dan J, Yan W, Cui J S, et al.Norcantharidin reverses cisplatin resistance and inhibits the epithelial mesenchymal transition of human non-small lung cancer cells by regulating the YAP pathway[J]. Oncol Rep, 2018,40(2): 609-620.
[26] Du H F, Yu L J, Meng Y F, et al.Norcantharidin enhances bortezomib-antimyeloma activity in multiple myeloma cells in vitro and in nude mouse xenografts[J]. Leuk Lymphoma, 2013, 54(3):607-618.
[27] Sun C Y, Zhu Y, Li X F, et al.Norcantharidin alone or in combination with crizotinib induces autophagic cell death in hepatocellular carcinoma by repressing c-Met-mTOR signaling[J]. Oncotarget, 2017, 8(70):114945-114955.
[28] 李宗宪, 刘秀萍, 刘厚强. 去甲斑蝥素联合FOLFOX4方案治疗晚期大肠癌40例[J]. 山东医药, 2010, 50(46):109.
[29] 赵悦友, 杨洪业, 刘桂仙,等. 去甲斑蝥素联合化疗治疗晚期肝癌[J]. 中国肿瘤临床与康复, 1997,4(3):75.
[30] 刘裕民, 张景勍, 游智梅,等. 去甲斑蝥素和吴茱萸碱联合处理对HepG2人肝癌细胞生长的抑制作用[J]. 细胞与分子免疫学杂志, 2014, 30(8):824-828.
[31] 刘世芬, 丁玉峰, 牛建一,等. 去甲斑蝥素联合紫杉醇对非依赖前列腺癌细胞的抑制作用[J]. 中国临床药理学杂志, 2017,33(15):1457-1459.
[32] Wang D, Yang C, Wang Z, et al.Norcantharidin combined with Coix seed oil synergistically induces apoptosis and inhibits hepatocellular carcinoma growth by downregulating regulatory T cells accumulation[J]. Sci Rep, 2017, 7(1):9373.
[33] 初玉平, 沈琳, 白羽. 去甲斑蝥素联合中药治疗老年晚期肝癌的疗效观察[J]. 世界中西医结合杂志, 2012, 7(9):765-767.
[34] 李在林. 去甲斑蝥素与淫羊藿联合对原发性肝癌的临床效果分析[J].中外医学研究,2015,13(26):8-9.
[35] 刘安, 单德琴. 肝复乐与去甲斑蝥素联用治疗中晚期肝癌[J]. 内蒙古中医药, 1998,4(36):6.
[36] Mo L. Xin J W, Xiao J S, et al., Norcantharidin enhances antitumor immunity of GM-CSF prostate cancer cells vaccine by inducing apoptosis of regulatory T cells[J]. Cancer Sci, 2018,109(7):2109-2118.